The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S. Department of Health and Human Services, has released a new advisory warning about the possible side effects, harms, and unknowns of CBD. The federal agency also makes the implication that cannabis dispensaries may sell safer products than gas stations and other stores.

The cannabinoid product has been available on store shelves since Congress approved the use of hemp in the 2018 Farm Act, and SAMHSA reports that demand for it is still rising. According to SAMHSA’s advisory, a variety of form factors, such as CBD-infused foods, topicals, fabrics and drinks, are now available at an estimated 270,000 retail stores countrywide.

According to the advisory, which quotes a survey done by prescription discount plan SingleCare, one in every three Americans reported using cannabinoid products in 2020. As a result of its widespread use, the agency urges that people be aware of the risks and dangers involved with using CBD products as well as the common misconceptions surrounding them.

A majority of the risks mentioned in the study, including inaccurate labeling, poor quality control and low safety standards, are brought on by the fact that CBD products are not federally regulated.

The FDA announced last month that it would not be developing rules to permit the marketing of CBD as a food or dietary supplement despite numerous requests for action from legislators, advocates and other stakeholders to do so. Instead, it declared that it would prefer to work with Congress to find a different course of action. Additionally, the agency denied citizen petitions asking for rulemaking on CBD marketing.

The warning makes no attempt to contrast CBD’s potential side effects with the problems associated with prescription drugs, such as opioids. Various studies have shown that the use of opioids to treat conditions such as chronic pain can be decreased by making regulated marijuana, including CBD products, more widely available.

Epidiolex, a prescription drug made of purified CBD that is meant to treat a rare type of childhood epilepsy, is the only CBD product that has received FDA approval to date. All other CBD products are sold as potential treatments for a range of medical conditions, with only a few having been proven effective through research.

According to survey results from 2019 cited by the agency, 40% of CBD users bought products from cannabis dispensaries. One-third of consumers (34%) received the products from retail locations while 27% bought it online and 12% got it from an undisclosed source.

While marijuana dispensaries are still illegal on the federal level, cannabis retailers, which are typically licensed and subject to strict state regulation, may provide better and more consistent CBD products than those offered by national retailers, according to SAMHSA. However, the organization also stated that depending on the state’s definition of acceptable CBD products, the goods sold at marijuana dispensaries that are not FDA approved may contain more than 0.3% THC.

The medicinal potential of cannabis has drawn the attention of many entities, such as India Globalization Capital Inc. (NYSE American: IGC), which have invested heavily into studying these substances with the aim of commercializing FDA-approved formulations from them.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study
• In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms
• IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s.

IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing treatment. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. “As millions of Alzheimer’s patients continue to suffer from agitation, anxiety, and depression, phase 2 clinical trials bring hope for a treatment,” the company reports.

In addition to IGC-AD1, IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs (https://cnw.fm/67wqT). The company’s TGR-63 product is being studied for its potential to decrease Alzheimer’s markers, including plaque buildup, while also decreasing cognitive decline and improving memory. The company also has undisclosed molecules involved in exploratory activities.

With no current FDA-approved drugs to treat in Alzheimer’s patients, the company clearly has found a place where it can establish a foothold. In fact, last year less than 7% of drugs in clinical trials were focused on treating neuropsychiatric symptoms of Alzheimer’s. The time has clearly come for IGC. “What we do is important,” the company states. “With no known cure, our formulations have the potential to change lives.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Over the past decade or so, a growing body of research has revealed that cannabis has significant therapeutic potential. Studies have found that cannabis can be effective against a host of medical conditions, including chronic pain, insomnia and anxiety, with none of the side effects typically observed with pharmaceutical use.

Even as dozens of American states and overseas territories now allow their residents to purchase and use cannabis for medical purposes, researchers across the world are still trying to understand the plant’s full therapeutic potential. A recent study published in “NatureScientific Reports” journal has provided evidence linking cannabis usage to lower blood pressure.

For their study, investigators conducted an analysis of data gathered from more than 91,000 subjects to assess the relationship between blood pressure and marijuana consumption. They found that current and lifetime users of the plant tend to have lower blood pressure levels and that the effect was more pronounced in women compared to men.

Alexandre Vallée, the study’s lead researcher, highlighted that past studies on the relationship between blood pressure and cannabis use relied on a limited population pool and rarely looked at how cannabis consumption affected the blood pressure of different genders. This time, Vallée and her team sourced data from the UK Biobank, where a whopping 156,959 volunteers provided information on their cannabis use and blood pressure.

The researchers excluded 65,798 individuals who had past cardiovascular events and currently used antidepressants and antihypertensive drugs. They then the measured diastolic and systolic blood pressures of the remaining participants two times and asked them to report their lifetime cannabis use habits via a questionnaire.

Those who admitted to using cannabis a long time ago were still classified as marijuana users while participants who had never used the drugs were used as study controls. The cannabis users were then separated into other groups, based on their level of cannabis use and also whether they were former or current users.

According to the study, heavy lifetime cannabis use was linked to a reduction on both diastolic blood pressure and systolic blood pressure in both genders. Furthermore, the decrease in blood pressure was more pronounced in women compared to men. The researchers also observed that current cannabis users of both genders also exhibited lower blood pressure levels.

However, they noted that while other studies had also shown a stronger relationship between cannabis use and systolic pressure compared to cannabis use and diastolic pressure, they still weren’t completely certain of the relationship between cannabis and blood pressure. In their report, the investigators added that cannabinoid content could play a role in affecting blood pressure, with some previous studies showing that both CBD and THC both induce vasorelaxation and lower blood pressure.

This therapeutic potential of marijuana is making it possible for entities such as India Globalization Capital Inc. (NYSE American: IGC) to focus on developing THC-based formulations for conditions such as chronic pain, which take a toll on millions of Americans each year.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Last week saw the launch of the Australian Cannabis Nurses Association (ACNA), a newly formed organization to provide nurses with peer support, education and advocacy regarding medicinal marijuana. Simone O’Brien, a nurse practitioner and licensed medical marijuana practitioner, founded the group alongside Jodie Davis and Deb Ranson. The organization desires that nursing programs at the undergraduate level cover the endocannabinoid system.

O’Brien developed an interest in medicinal marijuana after suffering a severe leg injury during a leave from work, which pushed her to research the potential benefits of the medication.

Australia legalized medical marijuana seven years ago through the Federal Parliament. However, a majority of the medications are considered unapproved therapies, and healthcare providers must obtain approval through the Commonwealth Therapeutic Goods Administration before issuing a prescription.

According to O’Brien, the new group will provide training on medicinal cannabis for nurses at all levels. Additionally, the ACMA will promote improved patient access and provide peer support for nurses. She stated that many patients visit their doctors, psychiatrists or psychologists and are told that cannabis won’t work for them; thus, the purpose of the organization is to let people know that cannabis medication is safe and suitable for a wide range of patient populations.

Prescriptions for the substance have increased dramatically since 2016, going from a small number to well over 100,000 in 2022. The ACMA is advising caution when using cannabinoids for therapeutic purposes, claiming that they are still in their experimental stages despite the growing number of studies. Additionally, the group emphasizes the need for additional high-quality studies since the available evidence is scant and inconclusive regarding the safety and efficacy of medicinal marijuana products.

Lucy Haslam, cofounder of the Australian Medicinal Cannabis Association (AMCA), called the creation of the ACNA “exciting,” stating that patients often face discrimination due to a lack of knowledge about medicinal cannabis. Haslam first began her advocacy for the legalization of medicinal cannabis in 2014 with the help of her son Dan, who became dependent on the drug after being told that he had terminal bowel cancer. February marked eight years since Dan passed away and seven years since Australia legalized medical marijuana.

The ACNA will officially launch during the first AMCA-sponsored medicinal marijuana awareness week. Currently, the Federal Parliament does not formally recognize the AMCA, but Haslam hopes this recognition will happen in the near future.

It is well that associations such as ACNA are being formed to teach nurses about medical marijuana, because with the rate at which various companies such as India Globalization Capital Inc. (NYSE American: IGC) are working to develop cannabis-based therapeutics, it won’t be long before the medical community has to look at these products as an addition to or even alternative to conventional medicines.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Wisconsin Governor Tony Evers (D) recently unveiled the state’s biennial budget proposal, which once more includes language supporting the legalization of both medical and recreational cannabis. The governor made it known that he intended to include the adult-use proposal in his request, despite a top Republican lawmaker’s warning that doing so might jeopardize talks on more moderate medical marijuana legislation.

He also stated that he would not be persuaded to drop the proposal owing to the fact that he promised to work for comprehensive legalization during the campaign and a majority of state voters support the change in law.

However, passing adult-use legislation through the GOP-controlled House will be a difficult task.

The main elements of Evers’ cannabis legalization proposal include:

• Wisconsin residents who are 21 years of age or older may buy and possess up to two ounces of cannabis for personal use. Nonresidents, on the other hand, may possess a quarter ounce.
• Those who are 21 years old and older may also cultivate up to six marijuana plants for personal use.
• Patients on medical cannabis may include those with incapacitating medical conditions.
• Cannabis market regulation and business license issuance would fall under the purview of the Department of Revenue, which supported legalization in its budget proposal this year.
• A 15% tax would be imposed on marijuana wholesalers, and a further 10% tax would be applied to adult-use marijuana sales at the retail level. The excise tax would not be collected from medical cannabis patients.
• Proceeds from sales would go to a community reinvestment fund, which would support mental-health and substance-abuse treatment programs.
• Individuals could petition the courts for a new judgment or for the expungement of their record for convictions involving actions that the law has made legal.
• Labor peace agreements would be necessary for marijuana companies with more than 20 workers.
• The DOR would have to institute competitive scoring in the licensing procedure, giving preference to candidates who can show they will make an effort to provide stable jobs for residents and ensure employee and customer safety, etc.
• Employees who use marijuana outside of work would be protected from discrimination.
• The bill would also do away with THC drug testing as a prerequisite for acquiring public benefits.

The governor’s office forecasts that legal cannabis sales will bring in $44.4 million in “segregated tax revenue” for the state in the 2025 fiscal year and an increase in state general fund tax revenue of $10.2 million.

Meanwhile, other companies such as India Globalization Capital Inc. (NYSE American: IGC) are focused on running R&D programs aimed at bringing to market cannabis-based formulations that are more efficacious in treating chronic pain and other indications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

In January, Senate Majority Leader Chuck Schumer (D-NY) convened a second meeting to discuss cannabis legislation for the 118th Congress. This time, he invited a group of Republican senators to strategize the next steps for drafting a bill that could pass. The first meet-up with Democratic colleagues occurred at the beginning of February.

In the recent meeting, the GOP leaders present included Senators Dan Sullivan (R-AK), Rand Paul (R-KY), and Steve Daines (R-MT). The aim of these meetings is to establish a mechanism through which legislators can reach a bipartisan agreement on marijuana reform bill goals in the current Republican-controlled Congress.

Cannabis supporters are hoping for cooperation on the SAFE Plus legislation, which the senate majority leader worked to promote in the last days of the previous session. The SAFE Plus bill was anticipated to include provisions for marijuana banking and expungements alongside other potential minor reforms.

The three Republican senators who took part in the meeting on Tuesday were all original signatories of the SAFE Banking Act from the previous Congress.

In the meantime, Sullivan and Senator Jon Tester (D-MT) filed legislation last week to advance study into marijuana’s therapeutic potential for army veterans. The committee is scheduled to vote on that bill on Thursday.

Last year, Schumer and Senator Cory Booker (D-NJ) introduced a comprehensive cannabis legalization bill, but it failed to receive the 60 votes needed to pass the Senate due to insufficient support. As a grand bargain, Schumer oversaw bicameral and bipartisan negotiations on the SAFE Plus agreement. Schumer blamed some Republican senators for sidetracking the bipartisan proposals after attempts to include the reform in the comprehensive defense and spending bill failed.

On Booker’s part, he claimed that ongoing problems with cannabis banking caused by prohibition led to a “marijuana crisis,” and while he believes reform is still possible, he has emphasized the difficulties of the new political climate on Capitol Hill.

However, Booker has come under fire from some stakeholders in particular for how his stance on banking legislation has changed over time. At one point, the senator vowed to thwart any attempts to advance a standalone SAFE Banking Act without capital constituents but then later expressed interest in reaching an agreement. In a previous interview given in the wake of last year’s election, the senator expressed his concern that if Democrats failed to pass the cannabis bill during the lame-duck period, it might take a long time to do so.

President Joseph Biden has not clearly stated his take on cannabis banking, although he has stated that states should be free to determine their own marijuana laws without interference from the federal government. His government has also raised its profile in support of cannabis reform since the widespread pardoning of minor marijuana possession in October.

Chances are high that marijuana industry operators such as India Globalization Capital Inc. (NYSE American: IGC) will closely follow any developments on Capitol Hill pertaining to marijuana policy reform.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The American Society of Addiction Medicine, a top addiction treatment organization, is advocating for the legalization of all drugs that are currently illegal in the name of racial equity and public health. The organization, which has always sided with antidrug advocates and opposed even the mildest cannabis reforms, has significantly changed its stance on drug-related policies in the past few years.

While the organization has advocated for decriminalizing marijuana since 2015, it is now urging the decriminalization of all drugs, including the elimination of criminal penalties for paraphernalia, citing the stigma and institutionalized racism that are deeply embedded in the nation’s drug policy.

The group released three policy statements on Feb. 9, 2023, in which it advocated for the elimination of harsh civil and criminal penalties for the possession of drugs and drug accouterments for adult-use as part of a broader set of interlinked legal and public health reforms intended to enhance several carefully chosen outcomes. In addition to legalizing drugs, ASAM argued that lawmakers take into account the possibility of expunging records of prior offenses of this nature so that citizens are not still ostracized for them. The organization cited Portugal’s decriminalization laws and claimed that the reform may result in health improvements based on the available data.

In light of the fact that even minor shifts in the legal distribution of some drugs can greatly increase the risk of addiction, especially for marginalized people, and the current research gaps in drug policy, the group stated that its recommendations purposefully don’t encompass developing a framework for accessing currently illicit drugs for personal use.

Other recommendations made by the organization include making it easier to obtain clemency for those found guilty of drug offenses without violence at the federal and state levels, doing away with the cocaine conviction differential, and funding studies that seek to assess different public health methodologies to the use of drugs with a focus on various drug laws and policies. The association also urged lawmakers to end housing restrictions based on nonviolent, substance-related activities and to abolish requirements for public assistance recipients to submit to drug testing.

The ASAM recommendations represent a substantial change from the organization’s prior stance on drug policies since its establishment in 1954.

In 2012, the group released a report urging doctors to oppose reform calls, but as adult-use cannabis became legal in more states, the group’s policy positions seemed to shift toward a focus on public health. Since then, the association has taken a more active role in promoting marijuana reform, even supporting legislation’s provisions that would federally codify states’ rights to determine their cannabis laws in 2020. However, it has refrained from outright endorsing the legalization of commercial marijuana markets.

ASAM’s push for ending cannabis criminalization is no surprise given that for-profit enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are making plenty of headway in taking cannabis-based formulations through the clinical-development process in a bid to obtain regulatory approval for those novel therapeutics, proving that marijuana does have medicinal potential.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Despite polls showing that most Americans favor legalizing cannabis and the fact that it has spread to red states such as Missouri where adult-use sales began last week, some lawmakers and lobbyists still think that major, revolutionary change such as federal legalization is still a long way off.

Even though there are some encouraging signs in Congress, such as support from South Carolina Representative Nancy Mace, there is still plenty of opposition, and the House appears to have “a lot on its plate” right now. Mace is a prominent conservative advocate for marijuana legalization.

One significant barrier is the perception that marijuana is not a priority for House Speaker Kevin McCarthy, who represents a conservative region of California where retail dispensaries for legal commercial cannabis are prohibited. There is also an understanding that crucial committees where marijuana-related legislation needs to be heard will instead act as roadblocks. One example is the House Judiciary Committee, which is currently led by Jim Jordan, an Ohio Republican.

Jordan has already stated that his top priorities are the infamous laptop owned by Hunter Biden, the president’s son, as well as the actions of the American intelligence community and immigration at the southern U.S. border.

Rep. Chip Roy, a Texas Republican who received a D- grade from NORML, replaced Ed Perlmutter, a retired Colorado Democrat who was the main proponent of the SAFE Banking Act, on that same committee.

The upcoming 2024 presidential election will further compound the obstacles to marijuana legalization. While some observers point out that there is some common ground on the issue of marijuana between conservatives in the Freedom Caucus such as Rep. Matt Gaetz and moderates such as Mace, others point out that Jordan could approve legislation without a full hearing.

In her proposal for federal legalization, Mace said on Friday that she would reintroduce the States Reform Act, which would exempt marijuana from the Controlled Substances Act and leave most of the remaining issues to be resolved by state law. Her bill will be added to a scheduling proposal created by Florida Republican Rep. Greg Steube.

Observers also anticipate the reintroduction of the SAFE Banking Act, which is likely to be sponsored by Ohio Republican Rep. Dave Joyce, as well as the reappearance of other bills that failed to make much progress during the previous Congress.

According to early predictions, even SAFE Banking will run into the same issues that hindered progress in December.

Democrats currently hold a slim 51–49 advantage in the Senate, with Pennsylvania Democrat John Fetterman—a steadfast advocate for marijuana legalization—occupying the extra seat. Therefore, Democrats’ priorities and those of Senate Majority Leader Chuck Schumer have a freer hand in significant committees.

However, it also means that any bill must receive the support of all members of the Democratic caucus and at least nine Republicans to overcome cloture in per the chamber’s filibuster rule.

The way things stand, enterprises looking to medicalize marijuana compounds such as India Globalization Capital Inc. (NYSE American: IGC) have a more certain outlook compared to those that are banking on federal policy reform.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Cannabis consumption lodges have been controversial since the first consumption lounge was launched in Los Angeles in 2019. Consumption lounges have made little headway in the years since, and they are still a rarity across most of America.

The situation is the same up north in Canada, where the country has had legal recreational cannabis for five years now but still hasn’t made any effort to craft a legal framework for permanent consumption lounges. The most regulatory authorities have done is issue temporary outdoor consumption licenses for events such as music festivals, but there has been little action, if any, to address the lack of public consumption lounges.

Like most American states with legal cannabis markets, Canada has outlawed the public consumption of cannabis and only allows users to consume cannabis in private residences. But, while the United States has taken some steps to build up the consumption lounge segment, with the lounges becoming increasingly common in Nevada and California, and New York opening its first cannabis consumption lounge late last year, Canadian authorities have made few moves toward growing the sector.

Postdoctoral fellow at the University of Guelph’s School of Hospitality and Food & Tourism Management Susan Dupej argues that marijuana consumption in Canada is still a grey area. Dupej, a student of marijuana tourism in Canada, states that the few entrepreneurs that have opened consumption lounges have been able to use their smarts to maneuver around Canada’s regulations to avoid running afoul of the law.

She explained that the scarcity of legal consumption lounges in Canada has been a missed opportunity that could have significantly increased the country’s cannabis tourism potential. Given that public consumption of cannabis is outlawed, tourists who would like to dabble in Canada’s adult-use cannabis market have nowhere to consume cannabis once they purchase it. Dupej stressed that Canada has to quickly figure out consumption lounge regulations and put them in place.

The federal government may have been in charge of legalizing recreational marijuana, but the country’s municipal and provincial governments in charge of regulating public smoking and vaping have been slow to take action. As it stands, none of the trio of the largest recreational cannabis markets in Canada have a single approved permanent consumption lounge. This means that these regions are missing out on profits from cannabis tourists who would have come over to Canada for its adult-use market.

It doesn’t seem that regulators will take any action on cannabis lounges soon; an Ontario attorney general spokesman revealed in a recent interview that the province did not expect any changes to the country’s cannabis framework.

For enterprises that are pursuing the development of FDA-approved cannabis therapeutics, such as India Globalization Capital Inc. (NYSE American: IGC), no such concerns about where the products will be used exists because approved medicines can be used anywhere.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating in the trial has reached four: three sites in the United States and one site in Canada. In addition, based on patient enrollment and interest in the study, the company plans to more than double the number of trial sites, from the planned 4 or 5 sites to between 10 and 12 sites. According to the report, the trial will include 146 participants, with one-half receiving a placebo and the other one-half receiving IGC-AD1. Over a six-week period, the trial will study the efficacy of IGC-AD1 in treating agitation in dementia from Alzheimer’s disease.

The company noted that it is hoping to offer the first natural tetrahydrocannabinol (“THC”)-based medication for treating agitation in dementia from Alzheimer’s disease. Another report highlight was net revenue for the company, which totaled $332,000, an increase of 133% compared to $142,000 in the three months ended Dec. 31, 2021. In addition, net revenue totaled $745,000 for the nine months ended Dec. 31, 2022, a 172% increase when compared to $275,000 for the nine months ended Dec. 31, 2021. “We are delighted with the progress made during this quarter, highlighted by the commencement of the phase 2 clinical trial for our drug candidate IGC-AD1 for the safety and efficacy of the drug on agitation in dementia due to Alzheimer’s disease,” said India Globalization Capital CEO Ram Mukunda in the press release. “This represents a milestone in our progress towards gaining FDA approval for IGC-AD1, which we believe has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose, natural, THC-based candidate currently undergoing FDA trials. Moreover, our sales of natural products, which include gummies and pain relief creams, are seeing increased traction in the market. We’re encouraged by our third-quarter results and look forward to driving continued expansion through the balance of fiscal 2023.”

To view the full press release, visit https://cnw.fm/kxRE6

About India Globalization Capital Inc.

India Globalization Capital IGC develops advanced cannabinoid-based formulations for treating diseases and conditions including, but not limited to, Alzheimer’s disease, period cramps (“dysmenorrhea”), premenstrual syndrome (“PMS”) and chronic pain. The Company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person Phase 2B safety and efficacy clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). The Company also markets two wellness brands, Holief™ and Sunday Seltzer™. Holief™ targets women experiencing premenstrual syndrome and menstrual cramps, and Sunday Seltzer™ is a lifestyle, hemp-infused energy beverage brand. The Company is headquartered in Maryland, USA, and has historically operated an infrastructure segment based in India. For more information, visit the company’s website at www.IGCInc.us.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.